Question

Dasatinib.

Hint:

Dasatinib is effective in patients with CML who have developed resistance to imatinib, providing a second-line treatment option.

Answer 1

Dasatinib is a multi-targeted kinase inhibitor primarily used in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It targets several tyrosine kinases, including BCR-ABL, SRC family kinases, and others that are involved in cancer cell proliferation.
Step 1: Mechanism of Action:
Dasatinib inhibits BCR-ABL, the abnormal protein produced by the Philadelphia chromosome, and other kinases that are important for the survival and growth of leukemia cells.
Step 2: Clinical Uses:
Dasatinib is primarily used to treat Philadelphia chromosome-positive CML and ALL in patients who are resistant or intolerant to other therapies, such as imatinib.
Step 3: Dosage and Administration:
Dasatinib is taken orally, with the dose adjusted based on the patient's condition and treatment response.